AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
57 hedge funds and large institutions have $218M invested in AVEO Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 12 reducing their positions, and 10 closing their positions.
337% more call options, than puts
Call options by funds: $6.61M | Put options by funds: $1.51M
90% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 10
54% more capital invested
Capital invested by funds: $141M → $218M (+$76.8M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
50% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 12
16% more funds holding
Funds holding: 49 → 57 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$12.8M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$8.95M |
| 3 |
Millennium Management
New York
|
+$2.58M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.2M |
| 5 |
SIM
Spark Investment Management
New York
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$8.35M |
| 2 |
PA
Perceptive Advisors
New York
|
-$8.03M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$5.65M |
| 4 |
Renaissance Technologies
New York
|
-$5.22M |
| 5 |
AC
Armistice Capital
New York
|
-$3.55M |
AVEO Hedge Fund Activity: Q3 2017 in Review
57 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q3 2017, worth a combined $218M — up 54% from $141M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AVEO positions and 10 closed out — a net gain of 9 holders — while 18 added to existing stakes and 12 trimmed.
The largest buyer was Polar Capital, opening a new position worth an estimated $12.8M. The largest seller was Point72 Asset Management, cutting an estimated $8.35M.
- 57 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q3 2017, up from 49 in Q2 2017.
- Funds reported $218M of AVEO Pharmaceuticals, Inc. stock for Q3 2017, up 54% quarter-over-quarter.
- 19 funds opened new AVEO Pharmaceuticals, Inc. positions in Q3 2017 and 10 closed out, a net change of +9 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q3 2017 was Polar Capital, an estimated $12.8M added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q3 2017 was Point72 Asset Management, an estimated $8.35M sold.
Based on aggregated 13F filings for Q3 2017.